secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2022-01-04T23:59:59+00:00
Accession:  0001558370-22-000028
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma appoints Mark Oki as CFO effective Jan 17, 2022; grants 100k inducement shares
--------------------------------------------------------------------------------

- Mark Oki named CFO; annual base salary of $415,000, target bonus 40% of base, and $50,000 signing bonus.
- Inducement award of 100,000 restricted shares granted under Nasdaq Rule 5635(c)(4), vesting over three years.
- Severance: termination without cause or for good reason triggers base salary, COBRA for 12 months, and vesting.
- Change-in-control provision: one times base salary plus target bonus, 12 months COBRA, full equity acceleration.
- Oki previously CFO of Vivus and Alexza; brings over 20 years pharma finance experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837022000028/0001558370-22-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837022000028/aytu-20220104x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer